Table 1 Patient information in this study
From: KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy
Patient | Age | Gender | Diagnosis | β-adrenergic blocker | ACE inhibitor |
|---|---|---|---|---|---|
Control-1 | 54 | Male | Ventricular septal defect | − | − |
Control-2 | 60 | Female | Mitral valve defect | − | − |
Control-3 | 47 | Female | Ventricular septal defect | − | − |
Control-4 | 61 | Male | Ventricular septal defect | − | − |
Control-5 | 49 | Male | Mitral valve defect | − | − |
Hypertrophy-1 | 58 | Female | Hypertrophic obstructive cardiomyopathy |  +  | − |
Hypertrophy-2 | 62 | Male | Hypertrophic obstructive cardiomyopathy |  +  |  +  |
Hypertrophy-3 | 65 | Male | Hypertrophic obstructive cardiomyopathy | − |  +  |
Hypertrophy-4 | 54 | Female | Hypertrophic obstructive cardiomyopathy | − |  +  |
Hypertrophy-5 | 56 | Male | Hypertrophic obstructive cardiomyopathy |  +  |  +  |